Genetic testing for hypertrophic cardiomyopathy offers the potential to identify at-risk mutation carriers before the development of established left ventricular hypertrophy.
Highlights the limitations of diagnosing hypertrophic cardiomyopathy solely based on left ventricular hypertrophy and emphasizes the potential of genetic testing for early identification of at-risk individuals.
T he greatest opportunity afforded by discovering the genetic basis of human heart disease is accurate prediction and prevention of illness. Hypertrophic cardiomyopathy (HCM) provides a paradigm to fulfill this opportunity. Human genetics research has identified many gene mutations that result in cardiac hypertrophy, of which HCM is the most common and well-characterized. Sarcomere gene mutations in HCM result in left ventricular hypertrophy (LVH), myocardial fibrosis and disarray, diastolic dysfunction, and increased risk for arrhythmias, sudden death, and heart failure. Making the clinical diagnosis of HCM currently hinges on identifying unexplained hypertrophy, but LVH is a sign of established disease only. This finding cannot identify at-risk mutation carriers and cannot discriminate HCM from other forms of cardiac hypertrophy, either genetic or acquired.
Carolyn Y. Ho (Mon,) conducted a review in Hypertrophic cardiomyopathy. Genetic testing for hypertrophic cardiomyopathy offers the potential to identify at-risk mutation carriers before the development of established left ventricular hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: